These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
566 related items for PubMed ID: 22155630
21. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population--a practical observation. Sun F, Zhang Y, Tian D, Zheng M, Liu L, Zhang R, Dai Z, Chen J, Li T, Lu H. Vaccine; 2011 Sep 02; 29(38):6527-31. PubMed ID: 21767595 [Abstract] [Full Text] [Related]
22. Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions. Purohit S, Alvarez O, O'Brien R, Andreansky S. Pediatr Blood Cancer; 2012 Dec 15; 59(7):1280-3. PubMed ID: 22628221 [Abstract] [Full Text] [Related]
23. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, Chotpitayasunondh C. Vaccine; 2012 Feb 01; 30(6):1108-14. PubMed ID: 22178515 [Abstract] [Full Text] [Related]
24. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. Pediatrics; 2006 Sep 01; 118(3):e570-8. PubMed ID: 16950948 [Abstract] [Full Text] [Related]
31. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation. Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H. Vaccine; 2012 Nov 06; 30(48):6864-70. PubMed ID: 22989690 [Abstract] [Full Text] [Related]
32. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ. Vaccine; 2010 Aug 31; 28(38):6221-7. PubMed ID: 20638454 [Abstract] [Full Text] [Related]
34. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Pediatr Infect Dis J; 2009 Jul 31; 28(7):563-71. PubMed ID: 19561422 [Abstract] [Full Text] [Related]
35. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Le Corre N, Thibault F, Pouteil Noble C, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B. Vaccine; 2012 Dec 14; 30(52):7522-8. PubMed ID: 23103195 [Abstract] [Full Text] [Related]
36. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G. Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951 [Abstract] [Full Text] [Related]
37. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia. Souza AR, Braga JA, de Paiva TM, Loggetto SR, Azevedo RS, Weckx LY. Vaccine; 2010 Jan 22; 28(4):1117-20. PubMed ID: 20116631 [Abstract] [Full Text] [Related]
38. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP. Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330 [Abstract] [Full Text] [Related]